Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine (Nasdaq: CMND) announced receipt of a notice of patent publication from the China National Intellectual Property Administration dated November 12, 2025, covering its proprietary non‑hallucinogenic compound 5‑methoxy‑2‑aminoindane (MEAI) for the treatment of depression.
The release notes that preclinical studies show MEAI may enhance mood regulation and reduce anhedonia, and that the patent application expands Clearmind’s intellectual property protections for MEAI across multiple jurisdictions and for several mental health and addiction indications.
Clearmind Medicine (Nasdaq: CMND) announced completion of treatment for the first patient cohort in its ongoing FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD) on November 10, 2025. Six patients have been enrolled and treated to date, with two sites at Johns Hopkins and four at Yale, and two additional sites in Israel activated.
The multinational, multicenter single- and multiple-dose study will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol cravings and consumption among treatment-seeking and non-treatment-seeking heavy drinkers. The company highlighted the commercial context, citing a market projected to reach about $20 billion by 2032.
Clearmind Medicine (Nasdaq: CMND) received a Nasdaq Listing Qualifications notice dated November 3, 2025, for failure to meet Nasdaq Listing Rule 5550(b)(1), which requires $2,500,000 minimum stockholders' equity.
The company reported $1,065,668 of stockholders' equity as of its Form 6-K for the three and nine months ended July 31, 2025. Clearmind has 45 calendar days (until December 18, 2025) to submit a compliance plan; Nasdaq may grant up to 180 days total if the plan is accepted.
Management is evaluating options to regain compliance, including conversion of previously announced convertible promissory notes (up to $10,000,000). To date $1,045,062 of notes converted into 885,000 common shares on October 30–31, 2025, and the company expects further conversions could demonstrate compliance, though acceptance is not assured.
Clearmind Medicine (NASDAQ: CMND) filed a patent application in South Korea covering compositions of its proprietary compound 5-methoxy-2-aminoindane (MEAI) for the treatment of depression on November 5, 2025. The filing is described as strengthening Clearmind’s global IP portfolio for MEAI, a non-hallucinogenic neuroplastogen intended to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without psychedelic effects.
Preclinical studies are reported to show MEAI’s potential to enhance mood regulation and reduce anhedonia. The company says the expanded IP now includes protections across multiple jurisdictions as it prepares for further clinical development and commercialization.
Clearmind Medicine (NASDAQ: CMND) announced publication of a U.S. patent application on Oct 31, 2025 expanding intellectual property coverage for its non‑hallucinogenic neuroplastogen MEAI (5‑methoxy‑2‑aminoindane) for treatment of cocaine addiction.
The filing emphasizes MEAI's proposed mechanism—modulation of serotonin and dopamine pathways—and positions the program against a disorder with no FDA‑approved pharmacological treatments. The release cites a global market estimate of $1.36 billion in 2025 growing to $2.03 billion by 2032, and frames the application as strengthening Clearmind's IP portfolio and pipeline strategy for non‑hallucinogenic neuroplastogens.
Clearmind Medicine (Nasdaq: CMND) announced completion of treatment for the first cohort in its FDA‑approved Phase I/IIa trial of CMND‑100, an oral MEAI‑based candidate for Alcohol Use Disorder (AUD). Six patients have been enrolled and dosed so far, including two at Johns Hopkins and four at Yale; two additional sites in Israel are activated. The multinational, single‑ and multiple‑dose trial will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol cravings and consumption. The release cites a market projection rising from ~$13.2B (2024) to ~ $20B by 2032, highlighting commercial opportunity. Trial registry: NCT05913752.
Clearmind Medicine (Nasdaq: CMND) announced that CEO Dr. Adi Zuloff-Shani will be a featured speaker at the “Women in Psychedelic Leadership: Driving Innovation & Governance” webinar on October 29, 2025 at 9:00 AM PT / noon ET.
Dr. Zuloff-Shani will discuss psychedelic research, governance, and therapeutic development—highlighting work on alcohol use disorder, cocaine addiction, and obesity—and share perspectives from her 20+ years in biomedical R&D. The webinar is hosted by the Psychedelic Association of Canada and available via Eventbrite; Clearmind invites investors, researchers, and stakeholders to register and learn about the company’s strategic direction in psychedelic medicine.
Clearmind Medicine (Nasdaq: CMND) appointed Mary-Elizabeth Gifford as Chief of Global Impact effective Oct 27, 2025 to lead US partnerships, governmental and regulatory engagement, and strategic alliances in Washington, D.C. and New York.
Gifford previously held the same role at Psyence BioMed and led public policy at the Center for Mind-Body Medicine. The company noted its 31 granted patents, ongoing clinical trials at Yale, Johns Hopkins and Hadassah, and a Scientific Advisory Board with faculty from Harvard, Yale, and Penn.
Clearmind Medicine (Nasdaq: CMND) enrolled the last patient in the first cohort of its FDA‑approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Oct 21, 2025. Six patients completed enrollment: two at Johns Hopkins and four at Yale. The multinational, multicenter, single‑ and multiple‑dose study will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol craving and consumption. All participants must want to reduce or stop drinking. Two additional sites in Israel are being activated to support further enrollment. Trial registration: NCT05913752.
Clearmind Medicine (Nasdaq: CMND) announced the publication of a U.S. patent application on October 20, 2025 for a combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines (e.g., PEA) targeting binge behavior disorders.
The application, filed through Clearmind’s collaboration with SciSparc, covers treatment of multiple binge behaviors including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct. Clearmind said this combination leverages MEAI’s neuroplastic effects with PEA’s synergistic pharmacology. The company noted it has filed 13 patents related to the collaboration and cited preclinical data supporting MEAI’s efficacy in mitigating addictive behaviors while preserving normal reward pathways.